Serum polyfluoroalkyl concentrations, asthma outcomes, and immunological markers in a case-control study of Taiwanese children

Environmental Health Perspectives

Volumn 121, Issue 4, 2013, Pages 507-513

  Dong, Guang Hui ^a,b   Tung, Kuan Yen ^c   Tsai, Ching Hui ^c   Liu, Miao Miao ^a   Wang, Da ^a   Liu, Wei ^d   Jin, Yi He ^d   Hsieh, Wu Shiun ^e   Lee, Yungling Leo ^c,f   Chen, Pau Chung ^c,e  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SAINT LOUIS UNIVERSITY   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

AEC; Asthma; ECP; IgE; Perfluorinated compounds

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOGLOBULIN E; PERFLUORO COMPOUND; PERFLUOROOCTANESULFONIC ACID; PROTEIN;

ADOLESCENT; ARTICLE; ASTHMA; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SCORING SYSTEM;

ADOLESCENT; ASTHMA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENVIRONMENTAL POLLUTANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILS; FEMALE; FLUOROCARBONS; HUMANS; IMMUNOGLOBULIN E; LEUKOCYTE COUNT; LOGISTIC MODELS; MALE; ODDS RATIO; QUESTIONNAIRES; TAIWAN; TANDEM MASS SPECTROMETRY;

EID: 84875892899     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1205351     Document Type: Article

References (39)

1. Akbari O, Stock P, DeKruyff RH, Umetsu DT. 2003. Role of regulatory T cells in allergy and asthma. Curr Opin Immunol 15:627-633.
2. Anderson-Mahoney P, Kotlerman J, Takhar H, Gray D, Dahlgren J. 2008. Self-reported health effects among community residents exposed to perfluorooctanoate. New Solut 18:129-143.
3. Bao J, Liu W, Liu L, Jin Y, Dai J, Ran X, et al. 2011. Perfluorinated compounds in the environment and the blood of residents living near fluorochemical plants in Fuxin, China. Environ Sci Technol 45:8075-8080.
4. Braissant O, Wahli W. 1998. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139:2748-2754.
5. Chen HH, Wang JY, Jan RL, Liu YH, Liu LF. 2008. Reliability and validity of childhood asthma control test in a population of Chinese asthmatic children. Qual Life Res 17:585-593.
6. Colavita AM, Reinach AJ, Peters SP. 2000. Contributing factors to the pathobiology of asthma. The Th1/Th2 paradigm. Clin Chest Med 21:263-277.
7. Conder JM, Hoke RA, De Wolf W, Russell MH, Buck RC. 2008. Are PFCAs bioaccumulative? A critical review and comparison with regulatory criteria and persistent lipophilic compounds. Environ Sci Technol 42:995-1003.
8. Corsini E, Avogadro A, Galbiati V, dell'Agli M, Marinovich M, Galli CL, et al. 2011. In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs). Toxicol Appl Pharmacol 250:108-116.
9. Declaration of Helsinki. 1990. 41st World Medical Assembly. Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organization 24:606-609.
10. Dong GH, Liu MM, Wang D, Zheng L, Liang ZF, Jin YH. 2011. Sub-chronic effect of perfluorooctanesulfonate (PFOS) on the balance of type 1 and type 2 cytokine in adult C57BL6 mice. Arch Toxicol 85:1235-1244.
11. Eisner MD, Katz PP, Yelin EH, Henke J, Smith S, Blanc PD. 1998. Assessment of asthma severity in adults with asthma treated by family practitioners, allergists, and pulmonologists. Med Care 36:1567-1577.
12. Fairley KJ, Purdy R, Kearns S, Anderson SE, Meade BJ. 2007. Exposure to the immunosuppressant, perfluorooctanoic acid, enhances the murine IgE and airway hyperreactivity response to ovalbumin. Toxicol Sci 97:375-383.
13. Frisbee SJ, Shankar A, Knox SS, Steenland K, Savitz DA, Fletcher T, et al. 2010. Perfluorooctanoic acid, perfluo-rooctanesulfonate, and serum lipids in children and adolescent: results from the C8 Health Project. Arch Pediatr Adolesc Med 164:860-869.
14. Giesy JP, Kannan K. 2001. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol 35:1339-1342.
15. Grasty RC, Bjork JA, Wallace KB, Wolf DC, Lau CS, Rogers RJ. 2005. Effects of prenatal perñuorooctane sulfonate (PFOS) exposure on lung maturation in the perinatal rat. Birth Defects Res B Dev Reprod Toxicol 74:405-416.
16. Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM. 2010. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. Environ Health Perspect 118:1762-1767.
17. Houde M, Bujas TA, Small J, Wells RS, Fair PA, Bossart GD, et al. 2006. Biomagnification of perfluoroalkyl compounds in the bottlenose dolphin (Tursiops truncatus) food web. Environ Sci Technol 40:4138-4144.
18. Kato K, Wong L-Y, Jia LT, Kuklenyik Z, Calafat AM. 2011. Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. Environ Sci Technol 45: 8037-8045.
19. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 2007. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99:366-394.
20. Lau C, Butenhoff JL, Rogers JM. 2004. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 198:231-241.
21. Lee KS, Park SJ, Kim SR, Min KH, Jin SM, Lee HK, et al. 2006. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. J Immunol 177:5248-5257.
22. Lindstrom AB, Strynar MJ, Libelo EL. 2011. Polyfluorinated compounds: past, present, and future. Environ Sci Technol 45: 7954-7961.
23. Loewen M, Basu S, Halayko AJ, Kozyrskyj A, Bondy G, Becker AB. 2011. The impact of a perfluorinated compound (PFC) on airway function in an allergic murine model [Abstract]. Am J Respir Crit Care Med 183:A3249.
24. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, et al. 2004. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 172:5790-5798.
25. Montefort S, Ellul P, Montefort M, Caruana S, Agius Muscat H. 2011. A decrease in the prevalence and improved control of allergic conditions in 13- to 15-yr-old Maltese children (ISAAC). Pediatr Allergy Immunol 22:e107-e111.
26. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. 2004. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113: 59-65.
27. Noorlander CW, van Leeuwen SP, Te Biesebeek JD, Mengelers MJ, Zeilmaker MJ. 2011. Levels of perfluorinated compounds in food and dietary intake of PFOS and PFOA in the Netherlands. J Agric Food Chem 59:7496-7505.
28. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115:1298-1305.
29. Olsen GW, Butenhoff JL, Zobel LR. 2009. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol 27:212-230.
30. Organisation for Economic Co-operation and Development. 2002. Hazard Assessment of Perfluorooctane Sulfonate (PFOS) and Its Salts. Available: http://www.oecd.org/dataoecd/23/18/2382880.pdf [accessed 9 January 2012].
31. Paul AG, Jones KC, Sweetman AJ. 2009. A first global production, emission, and environmental inventory for perfluoro octane sulfonate. Environ Sci Technol 43:386-392.
32. Pearce N, Aït-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. 2007. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 62:758-766.
33. Platts-Mills TA. 2001. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 164:S1-S5.
34. Renner R. 2001. Growing concern over perfluorinated chemicals. Environ Sci Technol 35:154A-160A.
35. Takacs ML, Abbott BD. 2007. Activation of mouse and human peroxisome proliferator-activated receptors (α, β/δ, γ) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci 95:108-117.
36. Tsai CH, Huang JH, Hwang BF, Lee YL. 2010. Household environmental tobacco smoke and risks of asthma, wheeze and bronchitic symptoms among children in Taiwan. Repir Res 11:11; doi: 10.1186/1465-9921-11-11 [Online 29 January 2010].
37. U.S. Environmental Protection Agency. Basic Information: Perfluorooctanoic Acid (PFOA) and Fluorinated Telomers. Available: http://www.epa.gov/opptintr/pfoa/pubs/pfoainfo.html [accessed 8 March 2013].
38. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. 2006. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-α, -β, and -γ, liver X receptor-β, and retinoid X receptor-α. Toxicol Sci 92:476-489.
39. Wang IJ, Hsieh WS, Chen CY, Fletcher T, Lien GW, Chiang HL, et al. 2011. The effect of prenatal perfluorinated chemicals exposures on pediatric atopy. Environ Res 111:785-791.